Welcome to our dedicated page for Dyne Therapeutics news (Ticker: $DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dyne Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dyne Therapeutics's position in the market.
Dyne Therapeutics (Nasdaq: DYN) has announced that its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 6, 2024, at 3:00 p.m. ET.
The event will be live-streamed on Dyne's website, with a replay available for 90 days. Dyne Therapeutics is a clinical-stage company focused on developing treatments for genetically-driven muscle diseases.
Dyne Therapeutics (Nasdaq:DYN), a clinical-stage muscle disease company, has successfully closed its public offering of 12,075,000 shares of common stock at $31.00 per share. This includes the underwriters' full exercise of their option to purchase an additional 1,575,000 shares. The gross proceeds reached approximately $374.3 million before deducting underwriting discounts, commissions, and offering expenses. Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities acted as joint book-running managers, while Oppenheimer & Co. and Raymond James served as co-managers. The offering was conducted under a shelf registration statement filed with the SEC on March 5, 2024.
Dyne Therapeutics, a clinical-stage company focused on muscle diseases, has announced the pricing for a public offering of 10,500,000 shares of its common stock at $31.00 per share, expected to generate $325.5 million in gross proceeds. The offering is set to close around May 24, 2024, with an additional option for underwriters to buy up to 1,575,000 more shares. Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are joint book-running managers, while Oppenheimer & Co. and Raymond James are co-managers. The offering is conducted under a previously filed S-3 registration with the SEC.
Dyne Therapeutics has announced an underwritten public offering of $300,000,000 worth of common stock. Additionally, the company may grant underwriters a 30-day option to purchase up to $45,000,000 of additional shares.
Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are managing the offering, with Oppenheimer & Co. and Raymond James acting as co-managers. The offering's completion is subject to market conditions, and no assurance is given regarding the size or terms.
This offering is based on a shelf registration statement filed with the SEC on March 5, 2024, which became effective upon filing. The terms will be disclosed in a final prospectus supplement to be filed with the SEC.
Dyne Therapeutics reported positive clinical data from its Phase 1/2 ACHIEVE trial of DYNE-101 for myotonic dystrophy type 1 (DM1) and its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy (DMD). DYNE-101 showed a 27% mean splicing correction and improvements in muscle strength and timed function tests in DM1 patients. DYNE-251 demonstrated a 7.6% mean muscle-adjusted dystrophin expression in DMD patients, significantly surpassing the standard of care levels. Both treatments exhibited favorable safety profiles, encouraging trends in functional improvements, and no serious adverse events. Dyne aims to seek expedited approvals with updates on registration pathways by the end of 2024.
Dyne Therapeutics (Nasdaq: DYN) will host a virtual investor event on May 20, 2024, at 8:00 a.m. ET to discuss new clinical data from its Phase 1/2 ACHIEVE and DELIVER trials. The ACHIEVE trial focuses on DYNE-101 for myotonic dystrophy type 1 (DM1) and has enrolled 56 patients. Efficacy data from various cohorts will be presented. The DELIVER trial evaluates DYNE-251 for Duchenne muscular dystrophy (DMD) and has enrolled 48 patients. Safety, tolerability, and efficacy data, including dystrophin expression, will be discussed.
Both trials aim to provide comprehensive pharmacokinetic and pharmacodynamic data. The event will be webcast live and available for replay for 90 days.
Dyne Therapeutics, Inc. (Nasdaq: DYN) reported financial results for Q1 2024 and recent business highlights. The company focuses on innovative therapeutics for muscle diseases, anticipating additional clinical data from the ACHIEVE and DELIVER trials in the second half of 2024. With a strong cash position, Dyne aims to initiate registrational cohorts by year-end.
